Evidence map›Paper›PMID 39948021›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Characterizing circulating biomarkers for childhood dementia disorders: A scoping review of clinical trials.

Arlene D'Silva, James Barnes, Jason Djafar, Kaustuv Bhattacharya, Jingya Yan, Shekeeb Mohammad, Sushil Bandodkar, Alexandra Johnson, Michel Tchan, Christina Miteff and 3 more

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arlene D'SilvaDepartment of Neurology, The Sydney Children's Hospitals Network, Sydney, Australia; Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, The University of New South Wales, Sydney, Australia; UNSW RNA Institute, The University of New South Wales, Sydney, Australia. Electronic address: a.dsilva@unsw.edu.au.
James BarnesDepartment of Neurology, The Sydney Children's Hospitals Network, Sydney, Australia; Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, The University of New South Wales, Sydney, Australia.
Jason DjafarDepartment of Neurology, The Sydney Children's Hospitals Network, Sydney, Australia; Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, The University of New South Wales, Sydney, Australia.
Kaustuv BhattacharyaSydney Children's Hospitals' Network, Westmead, NSW 2145, Australia; Clinical School, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
Jingya YanClinical School, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia; Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Clinical School, NSW, Australia.
Shekeeb MohammadClinical School, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia; Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Clinical School, NSW, Australia.
Sushil BandodkarSydney Children's Hospitals' Network, Westmead, NSW 2145, Australia; Clinical School, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
Alexandra JohnsonDepartment of Neurology, The Sydney Children's Hospitals Network, Sydney, Australia; Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, The University of New South Wales, Sydney, Australia.
Michel TchanDepartment of Genetic Medicine, Westmead Hospital, Westmead, NSW 2145, Australia; Faculty of Medicine and Health, University of Sydney, NSW, Australia.
Christina MiteffChildren, Young People and Families Directorate of Hunter New England Local Health District and John Hunter Children's Hospital, New Lambton Heights, NSW 2305, Australia.
Kristina L ElvidgeChildhood Dementia Initiative, Brookvale, NSW, 2100, Australia.
Russell C DaleClinical School, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia; Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Clinical School, NSW, Australia.
Michelle FarrarDepartment of Neurology, The Sydney Children's Hospitals Network, Sydney, Australia; Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, The University of New South Wales, Sydney, Australia; UNSW RNA Institute, The University of New South Wales, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Childhood dementias, a group of neurological disorders are characterised by neurocognitive decline, with physical and psychosocial impacts for individuals. With therapy available for <5 ​% of childhood dementias, there is a high level of unmet need. Integration of biomarkers in clinical trials are important to characterize distinctive biological activities and interrogate targets for therapeutic development. This study reviewed four clinical trial registries to examine circulating biomarkers in childhood dementias. Findings from 262 studies were synthesized across 49/72 (68 ​%) childhood dementia disorders. Disease-related biomarkers were associated with 1) the primary pathophysiology 2) downstream pathogenic events 3) drug-related pharmacokinetics, safety and/or tolerability. The predominant biological measures were metabolites linked to the primary pathophysiological pathway (102 measures, 185 studies), while use of cytoskeletal proteins (3 measures, 15 studies), inflammatory mediators (19 measures, 24 studies), oxidative stress-related analytes (15 measures, 8 studies), neurotransmitters or related neuro-metabolites (3 measures, 5 studies) were limited. A range of potential biomarkers are used in clinical trials; however, their use is inconsistent and under utilised among conditions. Development of a panel of biomarkers has potential to interrogate and link shared biological pathways across the heterogeneity of childhood dementias to exert a significant impact for the development of disease-modifying therapies.

Indexed as

BiomarkersClinical Trials as TopicDementiaChildHumansBiomarkersBiomarkersChildhood dementiaClinical trialsEndpointsMetabolomicsProteomics

Identifiers

PMID39948021
PMCPMC12014410

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.